252 related articles for article (PubMed ID: 31346162)
1. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
Wong M; Sun Y; Xi Z; Milazzo G; Poulos RC; Bartenhagen C; Bell JL; Mayoh C; Ho N; Tee AE; Chen X; Li Y; Ciaccio R; Liu PY; Jiang CC; Lan Q; Jayatilleke N; Cheung BB; Haber M; Norris MD; Zhang XD; Marshall GM; Wang JY; Hüttelmaier S; Fischer M; Wong JWH; Xu H; Perini G; Dong Q; George RE; Liu T
Nat Commun; 2019 Jul; 10(1):3319. PubMed ID: 31346162
[TBL] [Abstract][Full Text] [Related]
2. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
3. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
5. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
6. Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
Zhang L; Sokolowski N; Atmadibrata B; Liu T
Oncol Rep; 2014 Apr; 31(4):1935-9. PubMed ID: 24481781
[TBL] [Abstract][Full Text] [Related]
7. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
Yang J; AlTahan AM; Hu D; Wang Y; Cheng PH; Morton CL; Qu C; Nathwani AC; Shohet JM; Fotsis T; Koster J; Versteeg R; Okada H; Harris AL; Davidoff AM
J Natl Cancer Inst; 2015 Jun; 107(6):djv080. PubMed ID: 25925418
[TBL] [Abstract][Full Text] [Related]
8. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
9. JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex.
Gao WW; Xiao RQ; Zhang WJ; Hu YR; Peng BL; Li WJ; He YH; Shen HF; Ding JC; Huang QX; Ye TY; Li Y; Liu ZY; Ding R; Rosenfeld MG; Liu W
Mol Cell; 2018 Apr; 70(2):340-357.e8. PubMed ID: 29628309
[TBL] [Abstract][Full Text] [Related]
10. The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.
Tee AE; Ling D; Nelson C; Atmadibrata B; Dinger ME; Xu N; Mizukami T; Liu PY; Liu B; Cheung B; Pasquier E; Haber M; Norris MD; Suzuki T; Marshall GM; Liu T
Oncotarget; 2014 Apr; 5(7):1793-804. PubMed ID: 24742640
[TBL] [Abstract][Full Text] [Related]
11. Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor.
Jablonowski CM; Quarni W; Singh S; Tan H; Bostanthirige DH; Jin H; Fang J; Chang TC; Finkelstein D; Cho JH; Hu D; Pagala V; Sakurada SM; Pruett-Miller SM; Wang R; Murphy A; Freeman K; Peng J; Davidoff AM; Wu G; Yang J
Elife; 2024 Mar; 12():. PubMed ID: 38488852
[TBL] [Abstract][Full Text] [Related]
12. A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo.
Xiao RQ; Ran T; Huang QX; Hu GS; Fan DM; Yi J; Liu W
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2200753119. PubMed ID: 35969736
[TBL] [Abstract][Full Text] [Related]
13. JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation.
Wang F; He L; Huangyang P; Liang J; Si W; Yan R; Han X; Liu S; Gui B; Li W; Miao D; Jing C; Liu Z; Pei F; Sun L; Shang Y
PLoS Biol; 2014 Mar; 12(3):e1001819. PubMed ID: 24667498
[TBL] [Abstract][Full Text] [Related]
14. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
Lee YF; Miller LD; Chan XB; Black MA; Pang B; Ong CW; Salto-Tellez M; Liu ET; Desai KV
Breast Cancer Res; 2012 May; 14(3):R85. PubMed ID: 22621393
[TBL] [Abstract][Full Text] [Related]
15. JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.
Liu X; Si W; Liu X; He L; Ren J; Yang Z; Yang J; Li W; Liu S; Pei F; Yang X; Sun L
Mol Cancer; 2017 Nov; 16(1):175. PubMed ID: 29187213
[TBL] [Abstract][Full Text] [Related]
16. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
17. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.
Zhang Z; Yang Y; Zhang X
Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645
[TBL] [Abstract][Full Text] [Related]
18. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
[TBL] [Abstract][Full Text] [Related]
19. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
Zhang C; Lu X; Huang J; He H; Chen L; Liu Y; Wang H; Xu Y; Xing S; Ruan X; Yang X; Chen L; Xu D
Clin Transl Med; 2021 Feb; 11(2):e328. PubMed ID: 33634984
[TBL] [Abstract][Full Text] [Related]
20. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
Wan J; Liu H; Yang L; Ma L; Liu J; Ming L
Int J Cancer; 2019 May; 144(10):2489-2500. PubMed ID: 30125344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
